These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31192858)

  • 1. Psychologic Morbidity Among Psoriatic Arthritis Patients in Remission or With Low Disease Activity: A Comparison Between Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Wohl Y; Reitblat O; Lerman TT; Cohen O; Reitblat T
    J Clin Rheumatol; 2020 Sep; 26(6):260-264. PubMed ID: 31192858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
    Haugeberg G; Michelsen B; Kavanaugh A
    RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
    J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA.
    Santos H; Eusébio M; Borges J; Gonçalves D; Ávila-Ribeiro P; Faria DS; Lopes C; Rovisco J; Águeda A; Nero P; Valente P; Cravo AR; Santos MJ
    Acta Reumatol Port; 2017; 42(4):287-299. PubMed ID: 29342473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with longstanding pPatients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort.
    Cruz LV; Farani JB; Costa JR; de Andrade Águas JV; Ruschel B; de Almeida Menegat F; Gasparin AA; Brenol CV; Kohem CL; Bessa A; Forestiero F; Thies F; Palominos PE
    Adv Rheumatol; 2024 Jan; 64(1):3. PubMed ID: 38167571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe.
    Gottlieb A; Gratacos J; Dikranian A; van Tubergen A; Fallon L; Emir B; Aikman L; Smith T; Chen L
    Rheumatol Int; 2019 Jan; 39(1):121-130. PubMed ID: 30426237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission and biologic persistence rates: 12-year real-world data.
    Murray K; Turk M; Alammari Y; Young F; Gallagher P; Saber T; Fearon U; Veale DJ
    Arthritis Res Ther; 2021 Jan; 23(1):25. PubMed ID: 33441191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs?
    Martins A; Oliveira D; Nicolau R; Rocha TM; Bernardo A; Costa L; Pimenta S; Bernardes M
    Clin Rheumatol; 2024 Jan; 43(1):251-258. PubMed ID: 37957488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results.
    Ayan G; Farisogulları B; Bilgin E; Bolek EC; KübraYardımcı G; Duran E; Ozsoy Z; Uzun GS; Kilic L; Akdoğan A; Karadag O; Bilgen ŞA; Kiraz S; Ertenli Aİ; Kalyoncu U
    Clin Rheumatol; 2022 May; 41(5):1439-1446. PubMed ID: 35088209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.
    Furst DE; Tran M; Sullivan E; Pike J; Piercy J; Herrera V; Palmer JB
    Clin Rheumatol; 2017 Sep; 36(9):2045-2054. PubMed ID: 28238086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
    Behrens F; Rech J; Thaçi D; Zinke S; Rothnie KJ; Oefner Daamen C; Leipe J
    Mod Rheumatol; 2022 Jan; 32(1):87-95. PubMed ID: 32856975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?
    Coates LC; Lubrano E; Perrotta FM; Emery P; Conaghan PG; Helliwell PS
    J Rheumatol; 2019 Jan; 46(1):38-42. PubMed ID: 30219765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.